Kimberly-Clark Corp records impressive performance in Q2 2025 by witnessing a significant increase in sales and volume growth. The corporation outperformed estimates and increased its 2025 forecast. Meanwhile, it affirmed the second quarter results, displaying strength in earnings. The dividend growth trend continues with a quarterly payout of $1.26, extending the 53 year dividend growth streak. Several investment advisors reduced their holdings, while others considerably increased. A series of acquisition and selling of shares reflected the flexible movement of the company's stock. Unfortunately, the corporation reported sales below analyst estimates in Q2, highlighting a minor dip in income induced by divestitures. There are future business restructuring plans, which involves a huge investment to accelerate innovation and fuel growth. Kimberly-Clark is switching to Nasdaq, terminating its over a century-long NYSE legacy. Despite profit forecasts being lowered, investors are attracted to the long-term momentum stock. On another note, it declares a joint venture with Suzano leading to the formation of a global tissue company while selling a majority stake of its global tissue business to Suzano.
Kimberly-Clark Corp KMB News Analytics from Tue, 31 Dec 2024 08:00:00 GMT to Sat, 02 Aug 2025 21:48:04 GMT -
Rating 7
- Innovation 2
- Information 8
- Rumor 2
